CHARLES RIVER LABORATORIES (CRL) Fundamental Analysis & Valuation
NYSE:CRL • US1598641074
Current stock price
176.94 USD
-3.62 (-2%)
At close:
176.94 USD
0 (0%)
After Hours:
This CRL fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.
1. CRL Profitability Analysis
1.1 Basic Checks
- In the past year CRL was profitable.
- In the past year CRL had a positive cash flow from operations.
- Of the past 5 years CRL 4 years were profitable.
- Each year in the past 5 years CRL had a positive operating cash flow.
1.2 Ratios
- CRL has a Return On Assets (-2.02%) which is comparable to the rest of the industry.
- With a Return On Equity value of -4.56%, CRL perfoms like the industry average, outperforming 59.65% of the companies in the same industry.
- CRL's Return On Invested Capital of 6.60% is fine compared to the rest of the industry. CRL outperforms 77.19% of its industry peers.
- CRL had an Average Return On Invested Capital over the past 3 years of 6.85%. This is below the industry average of 11.38%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -2.02% | ||
| ROE | -4.56% | ||
| ROIC | 6.6% |
ROA(3y)1.3%
ROA(5y)3.17%
ROE(3y)2.98%
ROE(5y)8.14%
ROIC(3y)6.85%
ROIC(5y)7.38%
1.3 Margins
- The Operating Margin of CRL (12.51%) is better than 73.68% of its industry peers.
- In the last couple of years the Operating Margin of CRL has declined.
- CRL has a Gross Margin of 34.98%. This is in the lower half of the industry: CRL underperforms 63.16% of its industry peers.
- In the last couple of years the Gross Margin of CRL has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 12.51% | ||
| PM (TTM) | N/A | ||
| GM | 34.98% |
OM growth 3Y-8.99%
OM growth 5Y-4.24%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.66%
GM growth 5Y-0.96%
2. CRL Health Analysis
2.1 Basic Checks
- CRL has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
- The number of shares outstanding for CRL has been reduced compared to 1 year ago.
- The number of shares outstanding for CRL has been reduced compared to 5 years ago.
- CRL has a worse debt/assets ratio than last year.
2.2 Solvency
- An Altman-Z score of 2.47 indicates that CRL is not a great score, but indicates only limited risk for bankruptcy at the moment.
- CRL has a Altman-Z score (2.47) which is comparable to the rest of the industry.
- The Debt to FCF ratio of CRL is 4.13, which is a neutral value as it means it would take CRL, 4.13 years of fcf income to pay off all of its debts.
- The Debt to FCF ratio of CRL (4.13) is better than 73.68% of its industry peers.
- CRL has a Debt/Equity ratio of 0.68. This is a neutral value indicating CRL is somewhat dependend on debt financing.
- CRL has a worse Debt to Equity ratio (0.68) than 70.18% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.68 | ||
| Debt/FCF | 4.13 | ||
| Altman-Z | 2.47 |
ROIC/WACC0.63
WACC10.43%
2.3 Liquidity
- A Current Ratio of 1.29 indicates that CRL should not have too much problems paying its short term obligations.
- The Current ratio of CRL (1.29) is worse than 82.46% of its industry peers.
- A Quick Ratio of 1.02 indicates that CRL should not have too much problems paying its short term obligations.
- CRL has a worse Quick ratio (1.02) than 82.46% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.29 | ||
| Quick Ratio | 1.02 |
3. CRL Growth Analysis
3.1 Past
- The earnings per share for CRL have decreased by -0.39% in the last year.
- Measured over the past 5 years, CRL shows a small growth in Earnings Per Share. The EPS has been growing by 4.78% on average per year.
- The Revenue has decreased by -0.85% in the past year.
- The Revenue has been growing slightly by 6.55% on average over the past years.
EPS 1Y (TTM)-0.39%
EPS 3Y-2.61%
EPS 5Y4.78%
EPS Q2Q%-10.15%
Revenue 1Y (TTM)-0.85%
Revenue growth 3Y0.33%
Revenue growth 5Y6.55%
Sales Q2Q%-0.83%
3.2 Future
- The Earnings Per Share is expected to grow by 9.31% on average over the next years. This is quite good.
- CRL is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 3.54% yearly.
EPS Next Y8.35%
EPS Next 2Y9.28%
EPS Next 3Y9.35%
EPS Next 5Y9.31%
Revenue Next Year-0.59%
Revenue Next 2Y1.18%
Revenue Next 3Y2.21%
Revenue Next 5Y3.54%
3.3 Evolution
- The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
- When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. CRL Valuation Analysis
4.1 Price/Earnings Ratio
- With a Price/Earnings ratio of 17.21, CRL is valued on the expensive side.
- Based on the Price/Earnings ratio, CRL is valued cheaply inside the industry as 91.23% of the companies are valued more expensively.
- Compared to an average S&P500 Price/Earnings ratio of 27.38, CRL is valued a bit cheaper.
- CRL is valuated correctly with a Price/Forward Earnings ratio of 15.89.
- Based on the Price/Forward Earnings ratio, CRL is valued cheaper than 91.23% of the companies in the same industry.
- CRL is valuated cheaply when we compare the Price/Forward Earnings ratio to 38.20, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 17.21 | ||
| Fwd PE | 15.89 |
4.2 Price Multiples
- Based on the Enterprise Value to EBITDA ratio, CRL is valued cheaply inside the industry as 92.98% of the companies are valued more expensively.
- Based on the Price/Free Cash Flow ratio, CRL is valued cheaply inside the industry as 87.72% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 16.84 | ||
| EV/EBITDA | 11.97 |
4.3 Compensation for Growth
- The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates CRL does not grow enough to justify the current Price/Earnings ratio.
PEG (NY)2.06
PEG (5Y)3.6
EPS Next 2Y9.28%
EPS Next 3Y9.35%
5. CRL Dividend Analysis
5.1 Amount
- No dividends for CRL!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
CRL Fundamentals: All Metrics, Ratios and Statistics
176.94
-3.62 (-2%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)02-18 2026-02-18/bmo
Earnings (Next)05-07 2026-05-07/bmo
Inst Owners110.65%
Inst Owner Change-0.04%
Ins Owners0.84%
Ins Owner Change5.84%
Market Cap8.73B
Revenue(TTM)4.02B
Net Income(TTM)-144.34M
Analysts78.26
Price Target206.34 (16.62%)
Short Float %9.4%
Short Ratio4.31
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)1.93%
Min EPS beat(2)0.98%
Max EPS beat(2)2.88%
EPS beat(4)4
Avg EPS beat(4)9.75%
Min EPS beat(4)0.98%
Max EPS beat(4)23.68%
EPS beat(8)8
Avg EPS beat(8)9.14%
EPS beat(12)12
Avg EPS beat(12)7.96%
EPS beat(16)16
Avg EPS beat(16)6.74%
Revenue beat(2)1
Avg Revenue beat(2)0.06%
Min Revenue beat(2)-0.27%
Max Revenue beat(2)0.38%
Revenue beat(4)3
Avg Revenue beat(4)1.83%
Min Revenue beat(4)-0.27%
Max Revenue beat(4)3.74%
Revenue beat(8)6
Avg Revenue beat(8)1.34%
Revenue beat(12)9
Avg Revenue beat(12)1.37%
Revenue beat(16)11
Avg Revenue beat(16)1.18%
PT rev (1m)0.03%
PT rev (3m)2.47%
EPS NQ rev (1m)-0.22%
EPS NQ rev (3m)-25.21%
EPS NY rev (1m)-0.11%
EPS NY rev (3m)1.53%
Revenue NQ rev (1m)-0.15%
Revenue NQ rev (3m)-1.82%
Revenue NY rev (1m)-1.88%
Revenue NY rev (3m)-2.26%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 17.21 | ||
| Fwd PE | 15.89 | ||
| P/S | 2.17 | ||
| P/FCF | 16.84 | ||
| P/OCF | 11.84 | ||
| P/B | 2.76 | ||
| P/tB | 144.58 | ||
| EV/EBITDA | 11.97 |
EPS(TTM)10.28
EY5.81%
EPS(NY)11.14
Fwd EY6.29%
FCF(TTM)10.51
FCFY5.94%
OCF(TTM)14.95
OCFY8.45%
SpS81.38
BVpS64.14
TBVpS1.22
PEG (NY)2.06
PEG (5Y)3.6
Graham Number121.801 (-31.16%)
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -2.02% | ||
| ROE | -4.56% | ||
| ROCE | 8.35% | ||
| ROIC | 6.6% | ||
| ROICexc | 6.84% | ||
| ROICexgc | 14.71% | ||
| OM | 12.51% | ||
| PM (TTM) | N/A | ||
| GM | 34.98% | ||
| FCFM | 12.91% |
ROA(3y)1.3%
ROA(5y)3.17%
ROE(3y)2.98%
ROE(5y)8.14%
ROIC(3y)6.85%
ROIC(5y)7.38%
ROICexc(3y)7.1%
ROICexc(5y)7.66%
ROICexgc(3y)16.12%
ROICexgc(5y)18.95%
ROCE(3y)8.67%
ROCE(5y)9.34%
ROICexgc growth 3Y-11.32%
ROICexgc growth 5Y-5.63%
ROICexc growth 3Y-6.27%
ROICexc growth 5Y-3.36%
OM growth 3Y-8.99%
OM growth 5Y-4.24%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.66%
GM growth 5Y-0.96%
F-Score5
Asset Turnover0.56
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.68 | ||
| Debt/FCF | 4.13 | ||
| Debt/EBITDA | 2.36 | ||
| Cap/Depr | 54.34% | ||
| Cap/Sales | 5.46% | ||
| Interest Coverage | 4.94 | ||
| Cash Conversion | 81.47% | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.29 | ||
| Quick Ratio | 1.02 | ||
| Altman-Z | 2.47 |
F-Score5
WACC10.43%
ROIC/WACC0.63
Cap/Depr(3y)73.38%
Cap/Depr(5y)82.63%
Cap/Sales(3y)6.31%
Cap/Sales(5y)6.71%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-0.39%
EPS 3Y-2.61%
EPS 5Y4.78%
EPS Q2Q%-10.15%
EPS Next Y8.35%
EPS Next 2Y9.28%
EPS Next 3Y9.35%
EPS Next 5Y9.31%
Revenue 1Y (TTM)-0.85%
Revenue growth 3Y0.33%
Revenue growth 5Y6.55%
Sales Q2Q%-0.83%
Revenue Next Year-0.59%
Revenue Next 2Y1.18%
Revenue Next 3Y2.21%
Revenue Next 5Y3.54%
EBIT growth 1Y-8.84%
EBIT growth 3Y-8.7%
EBIT growth 5Y2.04%
EBIT Next Year25.17%
EBIT Next 3Y11.49%
EBIT Next 5Y9.93%
FCF growth 1Y3.37%
FCF growth 3Y20.69%
FCF growth 5Y6.41%
OCF growth 1Y0.42%
OCF growth 3Y5.98%
OCF growth 5Y6.18%
CHARLES RIVER LABORATORIES / CRL Fundamental Analysis FAQ
What is the fundamental rating for CRL stock?
ChartMill assigns a fundamental rating of 4 / 10 to CRL.
What is the valuation status of CHARLES RIVER LABORATORIES (CRL) stock?
ChartMill assigns a valuation rating of 6 / 10 to CHARLES RIVER LABORATORIES (CRL). This can be considered as Fairly Valued.
Can you provide the profitability details for CHARLES RIVER LABORATORIES?
CHARLES RIVER LABORATORIES (CRL) has a profitability rating of 4 / 10.
What is the valuation of CHARLES RIVER LABORATORIES based on its PE and PB ratios?
The Price/Earnings (PE) ratio for CHARLES RIVER LABORATORIES (CRL) is 17.21 and the Price/Book (PB) ratio is 2.76.
What is the financial health of CHARLES RIVER LABORATORIES (CRL) stock?
The financial health rating of CHARLES RIVER LABORATORIES (CRL) is 4 / 10.